Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been given a consensus rating of “Moderate Buy” by the nineteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $48.71.

A number of equities research analysts recently weighed in on NTLA shares. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research note on Friday, November 8th. The Goldman Sachs Group lowered their price objective on shares of Intellia Therapeutics from $19.00 to $12.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 14th. Morgan Stanley lowered shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $56.00 to $11.00 in a research report on Monday. BMO Capital Markets dropped their price target on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research note on Friday, January 10th. Finally, William Blair reiterated a “neutral” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a report on Monday, November 18th.

Insider Activity at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 28,735 shares of company stock worth $349,909 in the last 90 days. Company insiders own 3.20% of the company’s stock.

Institutional Trading of Intellia Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its stake in shares of Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock valued at $29,648,000 after purchasing an additional 98,865 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Intellia Therapeutics during the 2nd quarter valued at approximately $866,000. Sei Investments Co. grew its holdings in shares of Intellia Therapeutics by 24.7% during the 2nd quarter. Sei Investments Co. now owns 9,282 shares of the company’s stock worth $208,000 after acquiring an additional 1,837 shares during the period. Thrivent Financial for Lutherans bought a new position in shares of Intellia Therapeutics in the 2nd quarter worth approximately $679,000. Finally, Algert Global LLC lifted its stake in shares of Intellia Therapeutics by 307.0% in the 2nd quarter. Algert Global LLC now owns 68,372 shares of the company’s stock valued at $1,530,000 after purchasing an additional 51,572 shares during the period. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

NTLA opened at $10.12 on Thursday. Intellia Therapeutics has a one year low of $9.25 and a one year high of $34.87. The firm has a market capitalization of $1.03 billion, a P/E ratio of -1.86 and a beta of 1.83. The company has a fifty day moving average price of $12.41 and a 200-day moving average price of $17.78.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. Intellia Therapeutics’s revenue was down 24.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.38) earnings per share. On average, analysts expect that Intellia Therapeutics will post -5.09 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.